16,204
likes
3,174
comments
daily view 0
monthly view 0
Live Analytics
Comments 0
Psilocybin, Australian re scheduling Analytics Table
Income Estimates for Psilocybin, Australian re scheduling
Based on this YouTube video's total view count of 306K views and industry-standard rates, the estimated total earning is $215 - $614 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.
About Psilocybin, Australian re scheduling
Explore Psilocybin, Australian re scheduling with 306,901 views, 16,204 likes, and 3,174 comments. Experience the impact of this video content that has captured audience attention.
Re-scheduling of psilocybin and MDMA https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma/re-scheduling-psilocybin-and-mdma-poisons-standard-questions-and-answers On 3 February 2023, TGA Permit prescribing of MDMA for the treatment of post-traumatic stress disorder (PTSD) Psilocybin for treatment-resistant depression (TRD) Psychiatrists who are specifically authorised under the TGA’s Authorised Prescriber scheme, effective from 1 July 2023. Legal psilocybin prescriptions in Canada (January 2022) https://www.drugscience.org.uk/canadians-can-now-be-legally-prescribed-psilocybin/ The SAP allows healthcare practitioners to request limited access to drugs that are not authorized for sale in Canada. https://www.psychiatrist.com/jcp/depression/identifying-difficult-treat-depression-differential/ Treatment-resistant depression (TRD) is common Responsible for much of the burden of major depressive disorder worldwide. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial https://journals.sagepub.com/doi/10.1177/0269881116675512?url_ver=Z39.88-2003 Clinically significant anxiety and depression Common in patients with cancer Associated with poor psychiatric and medical outcomes Double-blind, placebo-controlled trial Intervention Single-dose psilocybin (0.3 mg/kg), 70 Kg = 21mg in conjunction with psychotherapy. Assessed at 7 weeks Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression, and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life. At the 6.5-month follow-up Psilocybin was associated with enduring anxiolytic and anti-depressant effects, 60–80% of participants continued with clinically significant reductions in depression or anxiety, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. Trial Registration: ClinicalTrials.gov Identifier: NCT00957359 Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists Medicines containing the psychedelic substances psilocybin, and MDMA (3,4-methylenedioxy-methamphetamine) Only conditions, currently sufficient evidence For potential benefits in certain patients, MDMA for treatment of post-traumatic stress disorder Psilocybin for treatment-resistant depression Acknowledges the current lack of options for patients with specific treatment-resistant mental illnesses https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma.pdf Patients may be vulnerable during psychedelic-assisted psychotherapy, requiring controls to protect these patients. There are currently no approved products containing psilocybin or MDMA that the TGA has evaluated for quality, safety and efficacy. However, this amendment will allow authorised psychiatrists to access and legally supply a specified ’unapproved’ medicine containing these substances to patients under their care for these specific uses.
About YouTube Real-Time View Count
With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.
Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.
Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.
Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.
Embed Widget
Parameters:
fullscreen=true- Fullscreen countergraph=true- Live graph chartcounter=0/1/2- Select counter (0=likes, 1=views, 2=comments)
URL
Click to copy the embed URL to your clipboard

